A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT ID: NCT07188896
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2026-02-28
2030-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm A: Cemiplimab, Fianlimab, and Ipilimumab
Cemiplimab and fianlimab will be co-administered by IV. Ipilimumab will be administered by IV.
Fianlimab
Fianlimab will be co-administered by IV.
Ipilimumab
Ipilimumab will be administered by IV.
Cemiplimab
Cemiplimab will co-administered by IV.
Arm B: Cemiplimab and Fianlimab
Cemiplimab and fianlimab will be co-administered by IV.
Fianlimab
Fianlimab will be co-administered by IV.
Cemiplimab
Cemiplimab will co-administered by IV.
Arm C: Nivolumab and Ipilimumab
Nivolumab and ipilimumab will be by IV. Nivolumab will be administered by IV after the combination.
Ipilimumab
Ipilimumab will be administered by IV.
Nivolumab
Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fianlimab
Fianlimab will be co-administered by IV.
Ipilimumab
Ipilimumab will be administered by IV.
Nivolumab
Nivolumab will be administered by IV. Maintenance nivolumab will then be administered by IV.
Cemiplimab
Cemiplimab will co-administered by IV.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years at the time of consent.
3. Karnofsky Performance Status ≥ 70% within 14 days prior to registration.
4. Histological or cytological evidence of renal cell carcinoma having a clear cell component
5. Advanced (not amenable to curative surgery or radiation therapy) or metastatic (AJCC Stage IV \[version 9\]) renal cell carcinoma.
6. Treatment naïve for systemic therapy for renal cell carcinoma including no prior neo/adjuvant systemic therapy
7. Measurable disease according to RECIST 1.1 within 28 days prior to registration.
8. Patient must have either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue sections, obtained from preferably a metastatic lesion, preferably within 3 months or no more than 12 months with an associated pathology report. If the metastatic lesion biopsy specimen does not contain at least 20 unstained slides, supplementation with primary kidney cancer tissue is acceptable.
9. Demonstrate adequate organ function as defined in the protocol. All screening labs to be obtained within 14 days prior to registration.
10. Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to registration.
11. Females of childbearing potential who are sexually active with a male able to father a child must be willing to abstain from penile-vaginal intercourse or must use an effective method(s) of contraception. Males able to father a child who are sexually active with a female of childbearing potential must be willing to abstain from penile-vaginal intercourse or use an effective method(s) of contraception.
12. Known HIV-infected subjects on effective anti-retroviral therapy with undetectable viral load and CD4 count above 350 either spontaneously or on a stable antiviral regimen within 6 months of registration are eligible for this trial. Testing is not required at screening unless mandated by local policy
13. Subjects with known chronic hepatitis B virus (HBV) infection, must have an undetectable HBV viral load (serum hepatitis B virus DNA PCR that is below the limit of detection) and be on suppressive therapy, if indicated.
14. Subjects with a history of hepatitis C virus (HCV) infection must have been treated and cured (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy). For subjects with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial. Testing is not required at screening unless mandated by local policy.
15. As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.
Exclusion Criteria
2. Any condition requiring ongoing ≥ 10 mg prednisone equivalent/day
3. Participants with a history of myocarditis.
4. If clinically indicated based on clinical assessment and any ECG abnormalities, optional troponin T (TnT) or troponin I (TnI) may be done as described in the protocol.
5. Ongoing or recent (within 2 years) evidence of an autoimmune disease that required systemic treatment with immunosuppressive agents. The following are allowed: vitiligo, childhood asthma that has resolved, residual hypothyroidism that requires only hormone replacement, psoriasis not requiring systemic treatment.
6. Central nervous system (CNS) metastases as described in the protocol.
7. Active infection requiring systemic therapy as described in the protocol.
8. Pregnant or breastfeeding as described in the protocol.
9. Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen, per treating physician discretion.
10. Subjects must not receive live attenuated vaccines within 4 weeks prior to Cycle 1 Day 1 or at any time during the study. Inactivated vaccines are allowed.
11. Known hypersensitivity to the active substances or to any of the excipients.
12. Currently participating in another study or participated in any study of an investigational agent or investigational device within 30 days of the first dose of study drug.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Regeneron Pharmaceuticals
INDUSTRY
Vanderbilt-Ingram Cancer Center
OTHER
Brian Rini
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian Rini
Sponsor-investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Rini, MD
Role: PRINCIPAL_INVESTIGATOR
Vanderbilt-Ingram Cancer Center
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HCRN GU23-651
Identifier Type: -
Identifier Source: org_study_id